Skip to main content

Table 2 The hydroxyproline values calculated in the different groups.

From: The therapeutic effect of the neuropeptide hormone somatostatin on Schistosoma mansoni caused liver fibrosis

  Group 1 Group 2 Group 1 vs. Group 2
No SOM treatment Uninf.: 1.06 ± 0.10
Acute: 9.37 ± 0.63
p-value: 0.01**
Chronic: 9.65 ± 0.96 Uninf.: 1.06 ± 0.10
Chronic: 9.65 ± 0.96
p-value: 0.007**
Acute: 9.37 ± 0.63
Chronic: 9.65 ± 0.96
p-value: 0.90 (NS)
1 day SOM treatment Acute: 9.37 ± 1.24 Uninf.: 0.85 ± 0.08
Chronic: 8.99 ± 0.61
p-value: <0.0001**
Acute: 9.37 ± 1.24
Chronic: 8.99 ± 0.61
p-value: 0.90 (NS)
2 day SOM treatment Uninf.: 0.81 ± 0.09
Acute: 4.76 ± 0.58
p-value: 0.007**
Acute (untreated): 9.37 ± 0.63
Acute (2d SOM): 4.76 ± 0.58
p-value: 0.01**
Uninf.: 0.93 ± 0.09
Chronic: 5.88 ± 1.13
p-value: 0.02*
Chronic (untreated): 9.65 ± 0.96
Chronic (2d SOM): 5.8 ± 1.13
p-value: 0.03*
Uninf. (17 wks.): 0.81 ± 0.09
Uninf. (21 wks.): 0.93 ± 0.09
p-value: 0.41 (NS)
Acute: 4.76 ± 0.58
Chronic: 5.88 ± 1.13
p-value: 0.41 (NS)
  1. SOM: somatostatin; Uninf.: uninfected; Inf.: infected; Wks.: weeks;
  2. *Significant difference (p < 0.05); ** significant difference (p < 0.01);
  3. NS: not significant difference